Search Results

You are looking at 101 - 110 of 812 items for :

  • "risk factor" x
  • Refine by Access: All x
Clear All
Full access

Anurag Saraf, Hannah J. Roberts, Jennifer Y. Wo, and Aparna R. Parikh

enlarged lateral nodes. Among enrolled patients, more than half had either mesorectal fascia involvement or cN2 disease, with 60% having ≥2 high-risk factors and 30% having ≥3 high-risk factors. The primary endpoint of 3-year disease-related treatment

Full access

Francis P. Worden and Huan Ha

risk factor for the increase in incidence of tonsillar cancer . Int J Cancer 2006 ; 119 : 2620 – 2623 . 9. D'Souza G Kreimer AR Viscidi R . Case-control study of human papillomavirus and oropharyngeal cancer . N Engl J Med 2007 ; 356

Full access

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, and Eunice S. Wang

. The panel has focused on outlining reasonable treatment options based on recent clinical trials and data from basic science, which may identify new risk factors and treatment approaches. In some areas, panel members have divergent opinions about the

Full access

Scott Cooper, Mohammed Zaher, and Gregory Diorio

.S. Surveillance, Epidemiology, and End Results registry (SEER). Clinical identification of risk factors for adverse outcomes will allow for patient-specific counseling on prognosis and intervention. Methods: Population-based data from SEER 18 was used to assess

Full access

Himani Aggarwal, Li Li, Gebra Cuyun Carter, Kathy Fraeman, and Ariel Berger

risk factors included alcohol use, diabetes, and distant metastases. Conclusions: HPV-positive status was associated with a decreased risk of mortality among OPC patients in this study. Despite the small sample size and potential violation of

Full access

Chunkit Fung, Sophie D. Fossa, Clair J. Beard, and Lois B. Travis

known cancer risk factors, 31 such as smoking. 11 Chamie et al. 30 conducted a retrospective study to determine if patients with stage I nonseminoma who forewent RPLND had higher risks of SMN than those who underwent RPLND, with the assumption that

Full access

Emma Gargus, Rebecca Deans, Antoinette Anazodo, and Teresa K. Woodruff

, 19 , 24 , 30 , 33 , 37 , 41 Prevalence of and Risk Factors for POI in Survivors Depending on patient factors, cancer diagnosis, and treatment exposures, the prevalence of POI in survivors of pediatric and AYA cancer ranged from 2.1% to 82

Full access

Michaela A. Dinan, Bradford R. Hirsch, and Gary H. Lyman

associated with an intermediate risk of FN in the range of 10% to 20%. For patients receiving myelosuppressive chemotherapy regimens with an intermediate risk of FN, guidelines recommend assessing patient-specific risk factors. Although many such factors have

Full access

Prashant Gabani, Emily Merfeld, Amar J. Srivastava, Ashley A. Weiner, Laura L. Ochoa, Dan Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michael J. Naughton, Cynthia Ma, and Imran Zoberi

applied to obtain the final multivariable model. In patients who did not experience pCR, the Kaplan-Meier method was used to estimate whether those with multiple risk factors had an increased risk of LRR compared with those with a single risk factor

Full access

William R. Kennedy, Christopher Tricarico, Prashant Gabani, Ashley A. Weiner, Michael B. Altman, Laura L. Ochoa, Maria A. Thomas, Julie A. Margenthaler, Souzan Sanati, Lindsay L. Peterson, Cynthia X. Ma, Foluso O. Ademuyiwa, and Imran Zoberi

-based NAC do not experience pCR, 8 , 9 and data are scarce regarding clinically identifiable prognostic risk factors in this cohort of patients who have residual disease after NAC. We recently identified risk factors for locoregional recurrence (LRR) in